Galvanize PEF System 2024 Reimbursement And Coding User Guide
BACKGROUND
ABOUT ALIYA SYSTEM FOR PULSED FIELD ABLATION OF SOFT TISSUE
The Aliya™ system is designed to ablate soft tissue through the delivery of pulsed electric fields (PEF) energy to target tissue. The high frequency, short duration energy is delivered to the target tissue to induce cell death while maintaining the extracellular matrix.
INDICATIONS FOR USE
The Aliya system is 510(k) cleared in the United States for the surgical ablation of soft tissue.
DISCLAIMER
Galvanize Therapeutics does not promote the off-label use of its products and nothing herein is intended to promote an off-label use of the Aliya System. The Aliya System is a tool for the surgical ablation of soft tissues, and is not intended to treat, cure, prevent or mitigate any specific disease or condition.
The information provided contains general reimbursement information and is presented for illustrative purposes. The information does not constitute reimbursement or legal advice. It is the provider’s sole responsibility to determine medical necessity, the proper site for delivery of any services, and to submit accurate and appropriate codes, charges and modifiers based on the services rendered and the patient’s medical condition.
It is also the provider‘s sole responsibility to understand and comply with Medicare national coverage determinations (NCD), Medicare local coverage determinations (LCD), and any other specific payer billing requirements established by relevant payers. Payer billing, coding and coverage requirements vary from payer to payer, may be updated frequently, and should be verified before treatment for limitations on diagnosis, coding, or service requirements. Galvanize Therapeutics recommends you consult with payers, reimbursement specialists, and/or legal counsel regarding all coding, coverage, and reimbursement matters. All coding and
billing submissions to the federal government and any other payer must be truthful and not misleading, and require full disclosure for the reimbursement of any service or procedure. Galvanize Therapeutics specifically disclaims any responsibility for actions or consequences resulting from the use of this information.
CPT® Copyright 2024 American Medical Association. All rights reserved CPT® is a trademark of the American
Medical Association. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT®, and the AMA is not necessarily recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. All trademarks are the property of their respective owners.
DISCLOSURE
Prior to using the Aliya System, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. For full prescribing information, please visit www.galvanizetherapeutics.com.
PHYSICIAN, HOSPITAL OUTPATIENT, AND ASC CODING
Medicare 2024 National Average Payment (Not Adjusted Geographically) | ||||||||
Service Provided | Physician Fee Schedule1 | ASC2Payment/Indicator | Hospital3 | |||||
CPT® | Description | Non-Facility (OBL) | Facility (-26) | APC/Indicator APC/ Indicator | OPPSPayment | |||
0600T* | Ablation, irreversible electroporation; 1 or more tumors per organ, including imaging guidance, when performed, percutaneous (Do not report 0600T in conjunction with 76940, 77002, 77013, 77022) | No national payment established | $ 6604 | J8 | 5362 | J1 | $9808 | |
0601T* | Ablation, irreversible electroporation; 1 or more tumors, including fluoroscopic and ultrasound guidance, when performed, open (Do not report 0601T in conjunction with 76940, 77002) | No national payment established | $ 6 4 81 | J8 | 5362 | J1 | $9808 |
*2024 CPT® Professional. Current Procedural Terminology (CPT®) is copyright 1966, 1970, 1973, 1977, 1981, 1983-2022 by the American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association (AMA).
CATEGORY III CPT® CODES
The Aliya PEF procedure may be reported using the Category III CPT® codes in the table above. These codes
specifically describe irreversible electroporation of tumors via a percutaneous or open approach. If any
other type of laproscopic, endoscopic, or bronchoscopic approach is performed an unlisted procedure code
may be reported. Unlisted CPT® codes or “not otherwise specified” CPT® codes allow physicians to report
procedures that do not have a more specific CPT® code. Reporting an unlisted code correctly with appropriate
documentation allows physicians and hospitals to submit coding for a procedure that does not have a specific
CPT® code. The procedures described by CPT® 0600T and 0601T include the imaging guidance procedures. Imaging guidance CPT® codes are not separately submitted on the CMS Form 1500 claim form.
Category III CPT® Codes are temporary codes for emerging technology, services and procedures that allow
for specific data collection associated with those services and procedures. According to the AMA CPT®, if a Category III code is available, it must be reported instead of a Category I unlisted code1 .
There are no assigned RVU’s or established physician payment for these Category III CPT® codes.
Reimbursement to the physician is at the payer’s discretion. Payers may request documentation of clinical efficacy to support coverage. Payers that have implemented the new Category III IRE codes may request documentation of clinical efficacy to support coverage. The following items are recommended to support your claim submissions:
- Copy of operative report
- Letter of medical necessity
- Copy of the FDA clearance letter
When submitting a Category III CPT® code, it is recommended that providers submit a narrative listing a Category I CPT® code that they feel is comparable in time, effort, complexity, and value to the service provided, suggesting that the payer value the service represented by the Category III CPT® code based on the value assigned to this comparable Category I CPT® code. It will be important to document the services provided in terms of resources and time for appropriate payment consideration for the professional component of the procedure.
THE CODES BELOW DO NOT PRESUME, ASSUME, OR INTEND TO PROMOTE THE USE OF THIS GENERAL TOOL IN ANY SPECIFIC ANATOMICAL LOCATION OR FOR ANY SPECIFIC TREAMENT BY THE HEALTHCARE PROVIDER. THIS REIMBURSEMENT GUIDE IS ONLY INTENDED TO IDENTIFY GENERAL SOFT TISSUE LOCATIONS.
KIDNEY ICD-10-PCS CODES AND MS-DRGS
ICD-10-PCS Codes (OCT 1, 2023 to SEPT 30, 2024)
The listed ICD-10-PCS codes are examples of codes that may apply for kidney ablation procedures.4 Each ICD-10-PCS may be grouped under a Medicare Severity-Diagnosis Related Group (MS-DRGs).5
Code | ICD-10-PCS Description4 | MS-DRG5 |
0T500ZZ | Destruction of right kidney, open approach | 656 – 661 |
0T503ZZ | Destruction of right kidney, percutaneous approach | 656 – 661 |
0T504ZZ | Destruction of right kidney, percutaneous endoscopic approach | 656 – 661 |
0T510ZZ | Destruction of left kidney, open approach | 656 – 661 |
0T513ZZ | Destruction of left kidney, percutaneous approach | 656 – 661 |
0T514ZZ | Destruction of left kidney, percutaneous endoscopic approach | 656 – 661 |
0T530ZZ | Destruction of right kidney pelvis, open approach | 656 – 661 |
0T533ZZ | Destruction of right kidney pelvis, percutaneous approach | 656 – 661 |
0T534ZZ | Destruction of right kidney pelvis, percutaneous endoscopic approach | 656 – 661 |
0T540ZZ | Destruction of left kidney pelvis, open approach | 656 – 661 |
0T543ZZ | Destruction of left kidney pelvis, percutaneous approach | 656 – 661 |
0T544ZZ | Destruction of left kidney pelvis, percutaneous endoscopic approach | 656 – 661 |
Medicare Severity-Diagnosis Related Groups (MS-DRGs)5,6 (OCT 1, 2023 to SEPT 30, 2024)
The following MS-DRGs may apply to kidney ablation procedures for Medicare patients. Other secondary diagnosis codes corresponding to additional conditions at the time of admission or developing subsequently, and having an effect on the procedures performed or length of stay during the same inpatient admission, may also be reported.
MS-DRG5 | MS-DRG Description | Relative Weight Hospital Payment | |
656 | KIDNEY & URETER PROCEDURES FOR NEOPLASM W/ MCC | 3 . 1 3 76 | $21,968 |
657 | KIDNEY & URETER PROCEDURES FOR NEOPLASM W/ CC | 1 . 8 4 42 | $ 12 ,9 12 |
658 | KIDNEY & URETER PROCEDURES FOR NEOPLASM W/O CC/MCC | 1 . 4 8 04 | $10,365 |
659 | KIDNEY & URETER PROCEDURES FOR NON-NEOPLASM W/ MCC | 2 . 58 89 | $ 1 8 ,126 |
660 | KIDNEY & URETER PROCEDURES FOR NON-NEOPLASM W/ CC | 1 . 3 4 59 | $ 9 , 4 2 3 |
661 | KIDNEY & URETER PROCEDURES FOR NON-NEOPLASM W/O CC/MCC | 1 .0 4 8 4 | $ 7, 3 4 0 |
ICD-10-CM7 Diagnosis Codes (OCT 1, 2023 to SEPT 30, 2024)
The listed ICD-10-CM diagnosis codes are examples of codes that may apply for kidney ablation procedures.
Code | ICD-10-CM Description (Diagnosis Codes) |
C64.1 | Malignant neoplasm of right kidney, except renal pelvis |
C64.2 | Malignant neoplasm of left kidney, except renal pelvis |
C64.9 | Malignant neoplasm of unspecified kidney, except renal pelvis |
C65.1 | Malignant neoplasm of right renal pelvis |
C65.2 | Malignant neoplasm of left renal pelvis |
C65.9 | Malignant neoplasm of unspecified renal pelvis |
C79.00 | Secondary malignant neoplasm of unspecified kidney and renal pelvis |
C79.01 | Secondary malignant neoplasm of right kidney and renal pelvis |
C79.02 | Secondary malignant neoplasm of left kidney and renal pelvis |
C7A.093 | Malignant carcinoid tumor of the kidney |
C80.2 | Malignant neoplasm associated with transplanted organ |
LIVER ICD-10-PCS CODES AND MS-DRGS
ICD-10-PCS Codes (OCT 1, 2023 to SEPT 30, 2024)
The listed ICD-10-PCS codes are examples of codes that may apply for liver ablation procedures.4 Each ICD-10-PCS may be grouped under a Medicare Severity-Diagnosis Related Group (MS-DRGs).5
Code | ICD-10-PCS Description4 | MS-DRG5 |
0F500ZF | Destruction of liver using irreversible electroporation, open approach | 356-358, 405-407 |
0F503ZF | Destruction of liver using irreversible electroporation, percutaneous approach | 356-358, 405-407 |
0F504ZF | Destruction of liver using irreversible electroporation, percutaneous endoscopic approach | 356-358, 405-407 |
0F510ZF | Destruction of right lobe liver using irreversible electroporation, open approach | 356-358, 405-407 |
0F513ZF | Destruction of right lobe liver using irreversible electroporation, percutaneous approach | 356-358, 405-407 |
0F514ZF | Destruction of right lobe liver using irreversible electroporation, percutaneous endoscopic approach | 356-358, 405-407 |
0F520FZ | Destruction of left lobe liver using irreversible electroporation, open approach | 356-358, 405-407 |
0F523FZ | Destruction of left lobe liver using irreversible electroporation, percutaneous approach | 356-358, 405-407 |
0F524FZ | Destruction of left lobe liver using irreversible electroporation, percutaneous endoscopic approach | 356-358, 405-407 |
Medicare Severity-Diagnosis Related Groups (MS-DRGs)5,6 (OCT 1, 2023 to SEPT 30, 2024)
The following MS-DRGs may apply to liver ablation procedures for Medicare patients. Other secondary diagnosis codes corresponding to additional conditions at the time of admission or developing subsequently, and having an effect on the procedures performed or length of stay during the same inpatient admission, may also be reported.
MS-DRG5 | MS-DRG Description | Relative Weight Hospital Payment | |
356 | OTHER DIGESTIVE SYSTEM O.R. PROCEDURES W/ MCC | 4 . 2787 | $29,958 |
357 | OTHER DIGESTIVE SYSTEM O.R. PROCEDURES W/ CC | 2 .1 9 6 8 | $ 15 , 381 |
358 | OTHER DIGESTIVE SYSTEM O.R. PROCEDURES W/O CC/MCC | 1 . 28 1 1 | $ 8 , 9 7 0 |
405 | PANCREAS, LIVER & SHUNT PROCEDURES W/ MCC | 5 . 5052 | $38,545 |
406 | PANCREAS, LIVER & SHUNT PROCEDURES W/ CC | 2 . 8 874 | $20, 216 |
407 | PANCREAS, LIVER & SHUNT PROCEDURES W/O CC/MCC | 2 . 1 5 1 0 | $15,060 |
ICD-10-CM7Diagnosis Codes (OCT 1, 2023 to SEPT 30, 2024)
The listed ICD-10-CM diagnosis codes are examples of codes that may apply for liver ablation procedures.
Code | ICD-10-CM Description (Diagnosis Codes) |
C22.0 | Liver cell carcinoma |
C22.1 | Intrahepatic bile duct carcinoma |
C22.2 | Hepatoblastoma |
C22.3 | Angiosarcoma of liver |
C22.4 | Other sarcomas of liver |
C22.7 | Other specified carcinomas of liver |
C22.8 | Malignant neoplasm of liver, primary, unspecified as to type |
C22.9 | Malignant neoplasm of liver, not specified as primary or secondary |
C78.7 | Secondary malignant neoplasm of liver and intrahepatic bile duct |
C7A.098 | Malignant carcinoid tumors of other sites |
C7A.1 | Malignant poorly differentiated neuroendocrine tumors |
C7A.8 | Other malignant neuroendocrine tumors |
C7B.02 | Secondary carcinoid tumors of liver |
C7B.8 | Other secondary neuroendocrine tumors |
D01.5 | Carcinoma in situ of liver, gallbladder and bile ducts |
LUNG ICD-10-PCS CODES AND MS-DRGS
ICD-10-PCS Codes (OCT 1, 2023 to SEPT 30, 2024)
The listed ICD-10-PCS codes are examples of codes that may apply for lung ablation procedures.4 0Each ICD-10-PCS may be grouped under a Medicare Severity-Diagnosis Related Group (MS-DRGs).5
Code | ICD-10-PCS Description4 | MS-DRG5 |
0B533ZZ | Destruction of Right Main Bronchus, Percutaneous Approach | 163 – 165 |
0B543ZZ | Destruction of Right Upper Lobe Bronchus, Percutaneous Approach | 163 – 165 |
0B553ZZ | Destruction of Right Middle Lobe Bronchus, Percutaneous Approach | 163 – 165 |
0B563ZZ | Destruction of Right Lower Lobe Bronchus, Percutaneous Approach | 163 – 165 |
0B573ZZ | Destruction of Left Main Bronchus, Percutaneous Approach | 163 – 165 |
0B583ZZ | Destruction of Left Upper Lobe Bronchus, Percutaneous Approach | 163 – 165 |
0B593ZZ | Destruction of Lingula Bronchus, Percutaneous Approach | 163 – 165 |
0B5B3ZZ | Destruction of Left Lower Lobe Bronchus, Percutaneous Approach | 163 – 165 |
0B5C3ZZ | Destruction of Right Upper Lung Lobe, Percutaneous Approach | 166 – 168 |
0B5D3ZZ | Destruction of Right Middle Lung Lobe, Percutaneous Approach | 166 – 168 |
0B5F3ZZ | Destruction of Right Lower Lung Lobe, Percutaneous Approach | 166 – 168 |
0B5G3ZZ | Destruction of Left Upper Lung Lobe, Percutaneous Approach | 166 – 168 |
0B5H3ZZ | Destruction of Lung Lingula, Percutaneous Approach | 166 – 168 |
0B5J3ZZ | Destruction of Left Lower Lung Lobe, Percutaneous Approach | 166 – 168 |
0B5K3ZZ | Destruction of Right Lung, Percutaneous Approach | 166 – 168 |
0B5L3ZZ | Destruction of Left Lung, Percutaneous Approach | 166 – 168 |
0B5M3ZZ | Destruction of Bilateral Lungs, Percutaneous Approach | 166 – 168 |
0B5N3ZZ | Destruction of Right Pleura, Percutaneous Approach | 163 – 165 |
0B5P3ZZ | Destruction of Left Pleura, Percutaneous Approach | 163 – 165 |
0B5T3ZZ | Destruction of Diaphragm, Percutaneous Approach | 163 – 165 |
0B5_0ZZ | Destruction of [see above], Open Approach | 163 – 165 |
Medicare Severity-Diagnosis Related Groups (MS-DRGs)5,6 (OCT 1, 2023 to SEPT 30, 2024)
The following MS-DRGs may apply to lung ablation procedures for Medicare patients. Other secondary diagnosis codes corresponding to additional conditions at the time of admission or developing subsequently, and having an effect on the procedures performed or length of stay during the same inpatient admission, may also be reported.
MS-DRG3 | MS-DRG Description | Relative Weight Hospital Payment | |
163 | MAJOR CHEST PROCEDURES W/ MCC | 4 . 7 13 6 | $33,003 |
164 | MAJOR CHEST PROCEDURES W/ CC | 2.5504 | $1 7, 85 7 |
165 | MAJOR CHEST PROCEDURES W/O CC/MCC | 1.8 76 4 | $ 13 , 13 8 |
166 | OTHER RESP SYSTEM O.R. PROCEDURES W/MCC | 4.0578 | $ 2 8 , 41 1 |
167 | OTHER RESP SYSTEM O.R. PROCEDURES W/ CC | 1 . 8198 | $ 12 , 742 |
168 | OTHER RESP SYSTEM O.R. PROCEDURES W/O CC/MCC | 1 . 35 5 7 | $ 94 9 2 |
ICD-10-CM7Diagnosis Codes (OCT 1, 2023 to SEPT 30, 2024)
The listed ICD-10-CM diagnosis codes are examples of codes that may apply for lung ablation procedures.
Code | ICD-10-PCS Description4 |
C34.00 | Malignant neoplasm of unspecified main bronchus |
C34.01 | Malignant neoplasm of right main bronchus |
C34.02 | Malignant neoplasm of left main bronchus |
C34.10 | Malignant neoplasm of upper lobe, unspecified bronchus or lung |
C34.11 | Malignant neoplasm of upper lobe, right bronchus or lung |
C34.12 | Malignant neoplasm of upper lobe, left bronchus or lung |
C34.2 | Malignant neoplasm of middle lobe, bronchus or lung |
C34.30 | Malignant neoplasm of lower lobe, unspecified bronchus or lung |
C34.31 | Malignant neoplasm of lower lobe, right bronchus or lung |
C34.32 | Malignant neoplasm of lower lobe, left bronchus or lung |
C34.80 | Malignant neoplasm of overlapping sites, unspecified bronchus or lung |
C34.81 | Malignant neoplasm of overlapping sites, right bronchus or lung |
C34.82 | Malignant neoplasm of overlapping sites, left bronchus or lung |
C34.90 | Malignant neoplasm of unspecified part, unspecified bronchus or lung |
C34.91 | Malignant neoplasm of unspecified part, right bronchus or lung |
C34.92 | Malignant neoplasm of unspecified part, left bronchus or lung |
C37 | Malignant neoplasm of thymus |
C38.4 | Malignant neoplasm of pleura |
C45.0 | Mesothelioma of pleura |
C76.1 | Malignant neoplasm of thorax |
C78.00 | Secondary malignant neoplasm of unspecified lung |
C78.01 | Secondary malignant neoplasm of right lung |
C78.02 | Secondary malignant neoplasm of left lung |
C78.1 | Secondary malignant neoplasm of mediastinum |
C7A.090 | Malignant carcinoid tumor of the bronchus and lung |
C7A.091 | Malignant carcinoid tumor of the thymus |
D02.20 | Carcinoma in situ of unspecified bronchus and lung |
D02.21 | Carcinoma in situ of right bronchus and lung |
D02.22 | Carcinoma in situ of left bronchus and lung |
D38.1 | Neoplasm of uncertain behavior of trachea, bronchus and lung |
D38.2 | Neoplasm of uncertain behavior of pleura |
D38.3 | Neoplasm of uncertain behavior of mediastinum |
D38.4 | Neoplasm of uncertain behavior of thymus |
PANCREAS ICD-10-PCS CODES AND MS-DRGS
ICD-10-PCS Codes (OCT 1, 2023 to SEPT 30, 2024)
The listed ICD-10-PCS codes are examples of codes that may apply for pancreas ablation procedures.4 Each ICD-10-PCS may be grouped under a Medicare Severity-Diagnosis Related Group (MS-DRGs).5
Code | ICD-10-PCS Description4 | MS-DRG5 |
0F5G0ZF | Destruction of pancreas using irreversible electroporation, open approach | 405-407, 628-630 |
0F5G3ZF | Destruction of pancreas using irreversible electroporation, percutaneous approach | 405-407, 628-630 |
0F5G4ZF | Destruction of pancreas using irreversible electroporation, percutaneous endoscopic approach | — |
Medicare Severity-Diagnosis Related Groups (MS-DRGs)5,6 (OCT 1, 2023 to SEPT 30, 2024)
The following MS-DRGs may apply to pancreas ablation procedures for Medicare patients. Other secondary 0diagnosis codes corresponding to additional conditions at the time of admission or developing subsequently, and having an effect on the procedures performed or length of stay during the same inpatient admission, may also be reported.
MS-DRG3 | MS-DRG Description | Relative Weight Hospital Payment | |
405 | PANCREAS, LIVER, & SHUNT PROCEDURES W/ MCC | 5 . 5052 | $38,545 |
406 | PANCREAS, LIVER, & SHUNT PROCEDURES W/ CC | 2 . 8 874 | $20,216 |
407 | PANCREAS, LIVER, & SHUNT PROCEDURES W/O CC/MCC | 2 . 1 5 1 0 | $15,060 |
628 | OTHER ENDOCRINE, NUTRIT & METAB O.R. PROC W/ MCC | 4 .01 4 5 | $28,108 |
629 | OTHER ENDOCRINE, NUTRIT & METAB O.R. PROC W/ CC | 2 . 2628 | $15,843 |
630 | OTHER ENDOCRINE, NUTRIT & METAB O.R. PROC W/O CC/MCC | 1 . 39 6 3 | $ 9, 7 7 6 |
ICD-10-CM7Diagnosis Codes (OCT 1, 2023 to SEPT 30, 2024)
The listed ICD-10-CM diagnosis codes are examples of codes that may apply for pancreas ablation procedures.
MS-DRG3 | ICD-10-CM Description (Diagnosis Codes) |
C25.0 | Malignant neoplasm of head of pancreas |
C25.1 | Malignant neoplasm of body of pancreas |
C25.2 | Malignant neoplasm of tail of pancreas |
C25.3 | Malignant neoplasm of pancreatic duct |
C25.4 | Malignant neoplasm of endocrine pancreas |
C25.7 | Malignant neoplasm of other parts of pancreas |
C25.8 | Malignant neoplasm of overlapping sites of pancreas |
C25.9 | Malignant neoplasm of pancreas, unspecified |
REIMBURSEMENT SUPPORT
For questions regarding coding, coverage, payment and other reimbursement information, please contacts us at: AliyaReimbursement@galvanizetx.com.
REIMBURSEMENT TERMINOLOGY
Term | Description |
CMS | Centers for Medicare and Medicaid Services |
ASC | Ambulatory Surgical Center |
OPPS | Outpatient Prospective Payment System |
APC | Ambulatory Payment Classification |
J1 | Paid under OPPS; all covered Part B services on the claim are packaged with the primary “J1” service for the claim, except services with OPPS status indicator of “F,” “G,” “H,” “L” and “U”; ambulance services; diagnostic and screening mammography; rehabilitation therapy services; services assigned to a new technology APC; self- administered drugs; all preventive services; and certain Part B inpatient services. |
J8 | Device-intensive procedure; paid at adjusted rate |
ICD-10-CM | International Classification of Diseases, 10th Revision, Clinical Modification |
ICD-10-PCS | International Classification of Diseases, 10th Revision, Procedure Coding System |
IPPS | Inpatient Prospective Payment System |
MS-DRG | Medicare Severity Diagnosis Related Group |
W/MCC | Major Complications and Comorbidities |
W/CC | With Complications and Comorbidities |
W/O CC/MCC | Without Complications or Comorbidities, and Without Major Complications and Comorbidities. |
Relative Weight | A numeric value that reflects the relative resource consumption for the DRG to which it is assigned |
SOURCES
- CMS Physician Fee Schedule. CMS-1784-F. https://www.cms.gov/medicare/medicare-fee-service payment/physicianfeesched/ puffs-federal-regulation-notices/cms-1784-f
- CMS ASC Payment. CMS-1786-FC ASC. https://www.cms.gov/medicare/payment/prospective-payment systems/ambulatory surgical-center-ask/ask-regulations-and/cms-1786-fc
- CMS OPPS Payment. CMS-1786-FC. https://www.cms.gov/medicare/payment/prospective-payment systems/hospitaloutpatient/regulations-notices/cms-1786-fc
- CMS, 2024 ICD-10 Procedure Coding System (ICD-10-PCS). https://www.cms.gov/medicare/coding billing/icd-10-codes/2024- icd-10-pcs
- CMS, 2024 ICD-10-CM/PCS MS-DRG v41, Definitions Manual. https://www.cms.gov/icd10m/FY2024 nprmversion41.0-fullcodecms/fullcode_cms/P0001.html
- CMS, [CMS-1785-F] 2024 Medicare Hospital Inpatient Prospective Payment System (IPPS) Final Rule; Federal Register.
https://www.govinfo.gov/content/pkg/FR-2023-08-28/pdf/2023-16252.pdf. Payment is calculated based on the national adjusted standardized amount $7,001.60. Actual Medicare payment rates will vary from adjustments by Wage Index and Geographic Adjustment Factor depending on geographic locality. Also note that any applicable coinsurance, deductible, and other amounts that are patient obligations are included in the payment amount shown. - Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS). International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM). https://www.cdc.gov/nchs/icd/icd-10 cm.htm. Updated June 29, 2023.
CAUTION: Federal (US) law restricts this device to sale by or on the order of a physician. Important information: Prior to use, refer to the Instructions for Use that are supplied with this device for indications, contraindications, side effects, suggested procedure, warnings and precautions. Galvanize and Aliya are trademarks and may be registered in the US and/or in other countries.
All rights reserved.
SLS-00022 Rev D 2/21/2024
3200 Bridge Pkwy Redwood City, CA 94065
Galvanizetherapeutics.com
Documents / Resources
![]() | Galvanize PEF System 2024 Reimbursement And Coding [pdf] User Guide PEF System, PEF System 2024 Reimbursement And Coding, PEF System, 2024 Reimbursement And Coding, Reimbursement And Coding, And Coding, Coding |